Asad Haider
Stock Analyst at Goldman Sachs
(2.52)
# 2,421
Out of 5,042 analysts
11
Total ratings
100%
Success rate
9.68%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Asad Haider
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JNJ Johnson & Johnson | Maintains: Buy | $186 → $212 | $190.40 | +11.34% | 2 | Oct 9, 2025 | |
| INVA Innoviva | Initiates: Sell | $17 | $17.71 | -4.01% | 1 | Sep 30, 2025 | |
| RPRX Royalty Pharma | Initiates: Buy | $42 | $37.26 | +12.72% | 1 | Sep 30, 2025 | |
| PCVX Vaxcyte | Initiates: Neutral | $38 | $42.24 | -10.04% | 1 | Sep 12, 2025 | |
| NAMS NewAmsterdam Pharma Company | Initiates: Neutral | $27 | $35.72 | -24.41% | 1 | Jul 17, 2025 | |
| BNTX BioNTech SE | Initiates: Neutral | $110 | $105.66 | +4.11% | 1 | May 29, 2025 | |
| LLY Eli Lilly and Company | Upgrades: Buy | $892 → $888 | $825.45 | +7.58% | 1 | Apr 8, 2025 | |
| ABBV AbbVie | Assumes: Neutral | $194 | $227.99 | -14.91% | 1 | Apr 8, 2025 | |
| BMY Bristol-Myers Squibb Company | Downgrades: Neutral | $67 → $55 | $43.83 | +25.48% | 1 | Apr 8, 2025 | |
| PFE Pfizer | Downgrades: Neutral | $32 → $25 | $24.76 | +0.97% | 1 | Apr 8, 2025 |
Johnson & Johnson
Oct 9, 2025
Maintains: Buy
Price Target: $186 → $212
Current: $190.40
Upside: +11.34%
Innoviva
Sep 30, 2025
Initiates: Sell
Price Target: $17
Current: $17.71
Upside: -4.01%
Royalty Pharma
Sep 30, 2025
Initiates: Buy
Price Target: $42
Current: $37.26
Upside: +12.72%
Vaxcyte
Sep 12, 2025
Initiates: Neutral
Price Target: $38
Current: $42.24
Upside: -10.04%
NewAmsterdam Pharma Company
Jul 17, 2025
Initiates: Neutral
Price Target: $27
Current: $35.72
Upside: -24.41%
BioNTech SE
May 29, 2025
Initiates: Neutral
Price Target: $110
Current: $105.66
Upside: +4.11%
Eli Lilly and Company
Apr 8, 2025
Upgrades: Buy
Price Target: $892 → $888
Current: $825.45
Upside: +7.58%
AbbVie
Apr 8, 2025
Assumes: Neutral
Price Target: $194
Current: $227.99
Upside: -14.91%
Bristol-Myers Squibb Company
Apr 8, 2025
Downgrades: Neutral
Price Target: $67 → $55
Current: $43.83
Upside: +25.48%
Pfizer
Apr 8, 2025
Downgrades: Neutral
Price Target: $32 → $25
Current: $24.76
Upside: +0.97%